We selected the HER2 oncogene because incidence of HER2+ breast cancer increases with age in humans (Figure 1A) and delivering HER2 via lentivirus has been successfully used to model breast cancer in young mice34–36, and because it represents a clinically relevant subtype not driven by hormonal changes. Here, ERBB2 is linked to breast carcinoma.